Filgrastim & Pegfilgrastim – USA

Filgrastim & Pegfilgrastim – USA

IPR decision (Feb. 15, 2018):

AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Status
IPR2016-01542
08/05/2016
02/17/2017
Apotex Inc.
US 8,952,138
(Claims 1–17, 19–24 are unpatentable AND claim 18 is patentable)
US 8,952,138 (Amgen; Jul 29, 2031)

1. A method of refolding a protein expressed in a non-mammalian expression system and present in a volume at a concentration of 2.0 g/L or greater comprising: (a) contacting the protein with a refold buffer comprising a redox component comprising a final thiol-pair ratio having a range of 0.001 to 100 and a redox buffer strength of 2 mM or greater and one or more of: (i) a denaturant; (ii) an aggregation suppressor; and (iii) a protein stabilizer; to form a refold mixture; (b) incubating the refold mixture; and (c) isolating the protein from the refold mixture.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved